Format

Send to

Choose Destination
Enferm Infecc Microbiol Clin. 2015 Nov;33(9):617-24. doi: 10.1016/j.eimc.2015.09.002. Epub 2015 Oct 23.

[Pneumococcal vaccines. New conjugate vaccines for adults].

[Article in Spanish]

Author information

1
Servicio de Medicina Preventiva y Epidemiología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: mcampins@vhebron.net.

Abstract

Pneumococcal infections are a significant cause of morbidity and mortality, and are one of the 10 leading causes of death worldwide. Children under 2 years have a higher incidence rate, followed by adults over 64 years. The main risk group are individuals with immunodeficiency, and those with anatomical or functional asplenia, but can also affect immunocompetent persons with certain chronic diseases. Significant progress has been made in the last 10 years in the prevention of these infections. Until a few years ago, only the 23-valent non-conjugate pneumococcal vaccine was available. Its results were controversial in terms of efficacy and effectiveness, and with serious limitations on the type of immune response induced. The current possibility of using the 13-valent conjugate vaccine in adults has led to greater expectations in improving the prevention of pneumococcal disease in these age groups.

KEYWORDS:

Adultos; Adults; Pneumococcal vaccines; Steptococcus pneumoniae; Streptococcus pneumoniae; Vacunas antineumocócicas

PMID:
26474708
DOI:
10.1016/j.eimc.2015.09.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center